Growing Market Reach ImpriMed has successfully deployed its technologies across more than 40 US states and performed over 22,000 blood cancer tests in veterinary medicine, demonstrating a strong presence in the animal healthcare market and potential for expanding into human oncology.

Recent Funding Success With a recent $23 million Series A round led by SoftBank Ventures Asia and multiple rounds of investment since 2021, ImpriMed has secured substantial capital, enabling continued innovation and expansion into new healthcare segments such as personalized human cancer treatment.

Strategic Industry Collaborations Participation in prominent industry events like the American Society of Hematology Annual Meeting and inclusion in Mayo Clinic’s Platform Accelerate program position ImpriMed as a key player, opening doors for partnerships with medical institutions and healthcare providers.

Technology and Data Leadership Utilizing advanced AI-driven drug response predictions with a tech stack including cloud services and machine learning models, ImpriMed offers cutting-edge solutions that can be tailored for large-scale clinical adoption, appealing to hospitals and research centers.

Expanding Facility and Capacity Relocation to a new Palo Alto facility underscores ImpriMed’s growth ambitions and readiness to scale its operations, making it an attractive partner for strategic collaborations and investment into expanding its healthcare solutions.